Edition:
India

People: Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.44USD
20 Sep 2019
Change (% chg)

$-0.01 (-0.69%)
Prev Close
$1.45
Open
$1.44
Day's High
$1.45
Day's Low
$1.40
Volume
403,972
Avg. Vol
163,278
52-wk High
$2.23
52-wk Low
$1.20

Harrington, John 

Dr. John J. Harrington, Ph.D., is an Executive Vice President, Chief Scientific Officer, Director of Athersys Inc. Dr. Harrington co-founded Athersys in 1995 and has served as our Chief Scientific Officer, Executive Vice President and Director since our founding. Dr. Harrington led the development of the RAGE technology, as well as its application for gene discovery, drug discovery and commercial protein production applications. He is a listed inventor on over 20 issued or pending United States patents, has authored numerous scientific publications, and has received numerous awards for his work, including being named one of the top international young scientists by MIT Technology Review in 2002. Dr. Harrington has overseen the therapeutic product development programs at Athersys since their inception and is also focused on the clinical development and manufacturing of MultiStem. During his career, he has also held positions at Amgen and Scripps Clinic. He received his B.A. in Biochemistry and Cell Biology from the University of California at San Diego and his Ph.D. in Cancer Biology from Stanford University.

Basic Compensation

Total Annual Compensation, USD 472,644
Restricted Stock Award, USD 218,112
Long-Term Incentive Plans, USD --
All Other, USD 343,603
Fiscal Year Total, USD 1,034,360

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gil Van Bokkelen

1,458,440

William Lehmann

1,051,870

John Harrington

1,034,360

Laura Campbell

635,641

Lee Babiss

--

Ismail Kola

--
As Of  31 Dec 2017